SEC Tracker
Get the app

AEON Biopharma AEON

AEON Biopharma: quarterly report (amended) for the quarter ended Sep 30, 2023

Form
10-Q/A
Filed
Period
Importance
Routine

Quarter ended Sep 30, 2023: net loss $56.3M

From the 10-Q/A 0001837607-24-000014, as tagged in its XBRL.

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when AEON Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. Biovie BIVI public float $8M, Dec 31, 2025
  3. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  4. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  5. Talphera TLPH public float $8M, Jun 30, 2025